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Testing tumor type dependent relations between  
expression of ER and PgR with Ki-67 values in a single 
series of 1180 invasive ductal cancer patients
Abstract
Background: Model of cancer-associated epigenetic changes (Kurbel S. 
Tumour Biol. 2013;34:2011-7) proposes that dysfunctional estrogen recep-
tors (ER), unable to adequately express progesterone receptors (PgR), beside 
in the ER+PgR– breast cancers might also be present in ER+PgR+ tumors 
showing weak PgR expression.
Methods: In 1180 patients with invasive ductal cancers, ER and PgR 
positivity were semiquantitatively classified in four groups: “0” means no 
positive cells; “1+” <10% positive cells; “2+” 11–30% positive cells; and “3+” 
31–100% positive cells. Tumors were divided in breast cancer types.
Results: Among patients older than 54, Luminal A and B1 tumors were 
frequently ER3+ (p<0.01), while PgR3+ tumors were more common among 
Luminal A patients younger than 55 (p=0.034), suggesting that in older 
Luminal A or B1 patients, high ER and low PgR expression is common. 
Among Luminal B2 patients, ER and PgR expression did not depend much 
on age or on their Ki–67 values.
The model predicted share of dysfunctional ERs was 7.32% (for Luminal 
A), 11.26% (B1), 12.62% (B2 & Ki–67<=20%) and 14.73% (B2 & Ki-
67>20%). The predicted values matched well with the found shares of 
ER3+PgR1+ tumors within these three types (p>0.10).
Conclusions: The results support heterogeneity among ER+PgR+ tumors. 
Future studies of ER+PgR+ phenotype variants are required since hypotheti-
cal dysfunctional ERs in some ER+PgR+ breast cancer patients might alter 
their endocrine treatment outcomes.
 
1. IntroductIon
Epidemiologic data of breast cancer features were analyzed in a recent theoretic paper (1) proposing a model with two groups of breast 
cancer phenotype features.
The first group of features descends from the epigenetic phenotype 
of breast tissue cells that have become cancer cells. Possible examples of 
these breast tissue associated epigenetic features include HER2 absence 
or HER2 weak expression (1+ and 2+) in breast tumors.
The second proposed gropup consists of new features acquired during 





1  Dept. of Internal Medicine, School of Medicine, 
Osijek, Croatia
2  Dept. of Pathology and Forensic Medicine, 
School of Medicine, Osijek, Croatia
3  Dept. of Radiology, School of Medicine, 
Osijek, Croatia
Correspondence: 
Branka Kristek MD, PhD 
School of Medicine 
J Huttlera 4, 31000 Osijek, Croatia 
E-mail: kristek.branka@kbo.hr
Received January 8, 2015.
Original scientific paper
S. Kurbel et al. Testing tumor type…
418 Period biol, Vol 116, No 4, 2014.
normal breast cells. A typical example among these cancer 
associated features is the HER2 overexpression (3+), since 
this level of HER2 expression is never found in normal 
breast ductal cells.
1.1 Functionality of estrogen and 
progesterone receptors
Several studies (cited in ref. 1) have shown that ER on 
breast cancer cells can often be considered as less active, 
or dysfunctional. In short, possible ER/PgR combinations 
can be summarized like this:
–  ER+PgR+ cancers: usually considered to have func-
tional ERs and estrogen binding promotes the PgR 
expression.
–  ER+PgrR– cancers: usually considered dysfunctional 
ER as they lack the ability to express PgRs.
–  ER–PgR+ cancers: this rare phenotype can also be 
considered as a case of dysfunctional PgR expression 
despite the lack of detectable ER in tumor cells.
–  ER–PgR– cancers: negative receptors suggest no es-
trogen dependency of tumor cells.
When considering estrogen receptor (ER) semiquanta-
tive expression, situation is more complex. Only a minor-
ity of normal breast cells has ERs (2, 3), suggesting that 
also only few of the progenitor cells are ER positive. In 
ref. 1 it was proposed that tissue specific ER expression 
has to be controlled by ligand binding, as it has been 
found in various normal estrogen target tissue (4–11). 
Two simple mechanisms are proposed to exist in cells with 
expressions of functional ER and PgR (1, 4): the first is 
that estrogen binding to ER stimulates PgR expression in 
the same cell, and the second mechanism is that proges-
terone binding to PgR reduces ER and PgR expression in 
the same cell.
The proposed model (1) was based on the idea that if 
both mechanisms are active in tumor cells with the 
ER+PgR+ phenotype, this cancer can be considered to 
have “functional” ER and PgR receptors. Only these tu-
mors are considered to have descended from ER+ breast 
tissue progenitor cells, so their ER and PgR status is a 
tissue specific epigenetic feature.
If ER positive tumors have developed from the ini-
tially ER negative progenitor cells, their ER expression 
must have been acquired during cancerogenesis. Al-
though it is possible that a fully functional ER and PgR 
expression can be acquired in this way, the model in ref. 
1 is focused on the possibility that tumors arising from 
ER negative progenitor cells can often express dysfunc-
tional ER receptors, unable to fully express PgR after es-
trogen binding. If the first of the proposed mechanisms 
is blocked, the resulting phenotype is ER+PgR– with “dys-
functional” ERs that do not promote the PgR expression 
after estrogen binding. This also means that in these ER+ 
cells with scarce, or no PgR molecules, progesterone ex-
posure cannot adequately reduce ER and PgR expressions.
The remaining phenotype is a rare ER–PgR+ that can 
be attributed to the tumor associated epigenetic PgR ex-
pression independent of estrogen binding to ER.
To apply this approach to reported data on steroid hor-
mone receptors in breast cancer patients, reported data 
were in ref. 1 pooled from several studies. The results sug-
gested that all ER+PgR–, ER–PgR+ and some of ER+PgR+ 
tumors possibly started from ER negative breast tissue 
progenitor cells.
1.2 the model predictions of Er 
functionality
Taken all together, the presence of functional ERs and 
functional PgRs can be considered as two separate events, 
each with its own probability. When tossing a fair coin, 
to calculate the probability of a certain outcome, number 
of times it appeared is divided by the number of tosses. 
With two coins, a certain combination of outcomes is 
expected to happen as a product of two probabilities.
So, if we are considering functional ER and function-
al PgR expression in breast cancers, the expected share of 
tumors with both receptors functional is in the model 
calculated by multiplying probability of ER+ (pER) with 
probability of PgR+ (pPgR) in all breast tumors. Since 
among breast tumors with the “functional” ER+PgR+ phe-
notype, the probability of functional ER equals the func-
tional PgR probability, the expected share of breast tu-
mors with “functional” ER+PgR+ is the square of pPgR (1).
The presented model uses this share as a conservative 
estimation of the expected share of tumors with the 
“functional” ER+PgR+ phenotype. Since the share of all 
ER+PgR+ tumors is larger, model suggests that a certain 
portion of tumors with this phenotype might be acquired 
during cancerogenesis and despite the presence of ERs 
and PgRs in tumor cells, one, or both receptors are pos-
sibly dysfunctional.
The cited model suggests that about 1/5 of all ER+PgR+ 
breast tumors in ref. 1 can be considered as an unex-
pected surplus of this phenotype, possibly linked to epi-
genetic ER expression in tumors developed from ER 
negative progenitor cells. This idea suggests that Luminal 
A and Luminal B are possibly more heterogenous tumor 
types than usually expected. This approach might explain 
variable response to endocrine therapy applied to all breast 
cancer patients with ER or PgR positivity.
Without a suitably detailed published data set, the only 
solution was to use a single institution experience in di-
agnosing more almost than 1200 IDC patients that has 
already been formed as a part of an ongoing research proj-
ect (219–2192382–2426), financed by the Croatian Min-
istry of Science.
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The aim of this study is to apply numeric methods 
described in the previous paper on real patient data and 
thus get more reliable answers on the possible mecha-
nisms behind the breast cancer phenotypes.
2. PAtIEnts, mAtErIAls And 
mEthods
2.1. Patients
In this study 1180 consecutive patients of ductal inva-
sive breast carcinoma (any stage) were included. All pa-
tients were diagnosed and treated in Osijek Clinical Hos-
pital from the time period January 2004 to December 
2012. All of the specimens were excisional biopsies or 
mastectomy specimens. A tumor grade was determined 
using Bloom and Richardson sheme (12, 13).
2.2. Immunohistochemistry
Each immunostained slide was evaluated for the pres-
ence of ER and PgR expression, HER2 protein overex-
pression, and Ki–67 proliferation activity. Immunohisto-
chemical staining was performed by standard 
avidin-biotin method (DAKO LSAB®2 System, HRP) 
using 4 µm sections from representative paraffin blocks. 
Nuclear staining with anti-ER, PgR, Ki-67 antibodies 
was sought and the percentage of positive cells per 500 
tumor cells was calculated. Of note, all ER-positive and 
PgR-positive cases showed staining in at least 1% of the 
DCIS and/or invasive tumor cell nuclei, whereas all ER-
negative and PgR-negative cases showed complete absence 
of tumor cell staining (but with staining of normal breast 
epithelial cell nuclei) (14).
ER and PgR cancer positivity was semiquantitative 
classified in 4 groups, according to the percentage of 
positive cells: “0” means no positive cells; “1+” up to 10% 
positive cells; “2+” 10% to 30% positive cells; and “3+” 
means 30% to 100% positive cells.
Tumor cells were considered positive for HER2 pro-
tein over-expression when greater than 10% of the cells 
showed strong membrane staining (equivalent to a score 
of 3+ in the DakoCytomation HercepTest). HER2 2+ 
result was only positive if confirmed by chromogene in 
situ hybridization for gene amplification. All immunos-
tains were initially reviewed and scored by two of the 
study pathologists. Hormone receptors were reviewed and 
accepted as negative if 100% of cells lacked nuclear im-
munostaining for hormone receptor.
According to ICH analysis results’, tumors were di-
vided into following five groups: Luminal A (ER+ and/or 
PgR+, HER2-negative, Ki-67<=20%), Luminal B1 (ER+ 
and/or PgR+, HER2-negative, Ki-67>20%), Luminal B2 
(ER+ and/or PgR+, HER2-positive, any Ki-67), HER2 
(ER–, PgR–, HER2-positive), and triple-negative (ER–, 
PgR–, HER2-negative) (15).
2.3. statistical analysis
Collected data were organized in 2x2 tables and differ-
ences from expected frequencies were checked by χ2 tests.
Methods used for calculation of model predictions are 
based on equations described in the previous paper (1), 
also listed as formulas within the tables of this paper.
3. rEsults
Since the tested model proposes that some of ER+PgR+ 
breast tumors got their ER during cancerogenesis started 
in steroid receptor negative progenitor cells, the first ques-
tion was whether among our patients some HER2 or 
Ki67 subgroups differed in their ER or PgR expression.
3.1. observed Ihc phenotype features 
in breast cancer types
Table 1. shows collected data according to breast can-
cer types (listed in the top section of Table 1). Potentially 
the most diverse tumors are Luminal B2 that can have 6 
phenotypic variants (3 steroid receptor phenotypes com-
bine with low or high Ki-67 values). Both triple negative 
and pure HER2 overexpressed tumors are expected to 
have only two subgroups, depending on their Ki67 values. 
Luminal A and Luminal B1 tumors can come in three 
steroid hormone variants, since they are separated by their 
Ki67 value (Luminal A are up to 20% Ki67 positive, Lu-
minal B1 have Ki67 values larger than 20%).
If we take this approach to our data (the middle section 
of Table 1) and calculate the expected frequencies (the 
bottom section of Table 1), the ER+PgR+ phenotype was 
more frequent than expected among our patients with low 
Ki67 values (457 pts. vs. expected 319.16), clearly suggest-
ing that among our patients tumors with both receptors 
tend to have lower Ki67 values and lack HER2 overex-
pression. Among women with Luminal B1 tumors, the 
observed number of ER+PgR+ tumors was less than ex-
pected (177 vs. 261.13), due to small share of tumors with 
high Ki67 values among all ER positive tumors. In HER2 
overexpressing tumors, number of ER+PgR+ tumors was 
less than expected, thus suggesting that among these pa-
tients HER2 overexpression might has been more impor-
tant than the steroid receptors during cancerogenesis. A 
lack of ER+PgR+ tumors with low Ki67 value was observed 
among Luminal B2 patients (82 vs 120.29). Among 
ER+PgR– Luminal B2 tumors, the incidence of high Ki67 
tumors exceeded the expected number (20 vs. 11.21).
Among pure HER2 overexpressed tumors, 98 of them 
showed high Ki-67 values, while only 34.37 were expect-
ed. On the other hand, among triple negative tumors high 
Ki67 values were found in 123 tumors, while it was ex-
pected to be only in 91.18, clearly suggesting that some 
HER2 and steroid receptor independent mechanism ex-
ists in these tumors and force them to increase their mi-
totic activity.
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If we compare expected and observed frequencies, it is 
obvious that the statistical difference is mainly caused by 
receptor negative tumors (ER–PgR–) and tumors with both 
receptors (ER+PgR+). The other two combinations (ER+PgR– 
and ER–PgR+) did not differ much from the expected values 
when distributed by their HER2 and Ki-67 values.
If we take a close look on patients with ER–PgR– tu-
mors, it is obvious that they had an increased share of 
tumors with high Ki-67 values (98 vs 34.37 for HER2 
overexpressing tumor and 123 vs. 91.18 for HER2 nega-
tive tumors). These results also suggest that tumors lack-
ing sex hormone receptors were more dependent on 
HER2 expression and other putative mechanisms behind 
their high Ki-67 values.
3.2. distribution of semiquantatively 
estimated Er and Pgr among breast 
tumor types
The next stage in analysing our patients data was to 
use semiquantitavely assesed ER and PgR presence in tu-
mor tissue, instead the conventional positivity used in 
Table 1.
Table 2 shows distributions focused on age and Ki-67 
as factors that affect distributions of ER or PgR:
–  Reported frequencies of ER expression differed from 
the expected distribution according to age in older 
Luminal A and older Luminal B1 patients.
–  Among 320 older Luminal A patients, 310 had ER3+ 
tumors (p<0.0001). It is interesting that PgR3+ ex-
pression in Luminal A patients was more common 
among younger patients, 102 out of 120 younger 
patients were PgR3+ (p=0.034). This finding suggest 
that both ER ligands and functional ERs were more 
common among younger Luminal A patients. In 
older patients ER functionality and ligand exposure 
might have been to low to stimulate PgR expression.
–  In older Luminal B1 patients, 167 out of 175 patients 
were ER3+ (p=0.0089), while PgR expression in these 
patients was age unrelated (p=0.1316).
–  In Luminal B2 patients, regardless of the Ki67 value, 
ER and PgR expressions were almost unrelated to 
age, suggesting that the ER functionality was less 
important in this tumor type, possibly due to HER2 
overexpression.
TablE 1
Distribution of invasive ductal breast cancer patients according to their immunohistochemical features.
Ki67 value (%) HER2 overexpression Breast tumor steroid receptor phenotypes
ER+PgR+ ER+PgR– ER–PgR+ ER–PgR–
Breast cancer types: phenotypic variants
<=20%
Negative Luminal A Triple-negative
Positive Luminal B2 HER2-over-exressed
>20%
Negative Luminal B1 Triple-negative
Positive Luminal B2 HER2-over-exressed
Number of breast cancer patients Row Total
<=20%
Negative 457 33 6 31 527
Positive 82 13 0 27 122
Total 539 46 6 58 649
>20%
Negative 177 25 5 123 330
Positive 83 20 0 98 201
Total 260 45 5 221 531
Total 799 91 11 279 1180
Expected frequencies χ2 =305.736, df=10, p<0.00001 Row Total
<=20%
Negative 319.16 36.35 4.39 111.45 471.35
Positive 120.29 13.70 1.66 42.00 177.65
Total 439.45 50.05 6.05 153.45 649.00
>20%
Negative 261.13 29.74 3.60 91.18 385.65
Positive 98.42 11.21 1.36 34.37 145.35
Total 359.55 40.95 4.95 125.55 531.00
Total 799.00 91.00 11.00 279.00 1180.00
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3.3. model predictions of dysfunctional 
estrogen receptors
Table 3. is an attempt to estimate how much of the here 
presented patients might have acquired steroid receptors 
during cancerogenesis, beside the already recognized dys-
functional ER in the ER+PgR– phenotype.
Calculated results in Table 4. suggest that the greatest 
share of dysfunctional steroid receptors was expected in 
Luminal B2, particularly in the here proposed subtype 
with high Ki-67. For the comparison purposes only, the 
last rows shows numbers of patients with weak PgR phe-
notypes, and these data are not far from the predicted 
tumors with potentially dysfunctional ERs, suggesting 
that recognizing subtle difference in ER & PgR expression 
in breast tumors might be important.
4. dIscussIon
Our understanding of the breast cancer occurrence 
largely depends on the idea that estrogen levels are associ-
ated with an increased risk for the development of breast 
cancer (16,17). Estrogen receptor (ER) and progesterone 
receptor (PR) status at the time of breast carcinoma sur-
gery is used as a marker of both prognosis and hormone 
dependency to guide adjuvant therapy (18). Estrogen 
stimulates the proliferation of breast cancer cells and 
regulates the expression of other proteins, including the 
progesterone receptor (19).
It has been recognized that the presence of estrogen or 
progesterone receptors typically suggests slower-growing 
tumors, amenable to hormonal manipulation (20). Breast 
cancers classified by ER and PR status might represent 
diseases with different etiologies and clinical courses (21-
24). However, most of the reported studies are inconclu-
sive when considering this issue. It is reported that ER 
negative/PR positive breast carcinomas are biologically 
different from ER positive/PR positive tumors and have 
a poor clinical outcome (21). In 1556 breast cancer pa-
tients, risks regarding menstrual and reproductive (parity 
and lactation) characteristics, alcohol consumption, and 
family history were similar in patients with ER positive/
PR positive and ER negative/PR negative tumors, while 
observed differences were related to age, race, and recre-
ational exercise at 12–13 years of age (23). The conclusion 
was that these results only modestly support the hypoth-
esis of two diseases with differing etiologies. In another 
study, levels of free and bound estradiol in archived blood 
samples were compared between postmenopausal breast 
TablE 2
Age and Ki-67 dependent distributions of semiquantative ER and PgR expressions. Reduced ER 
expression was more common in younger Luminal A and Luminal B1 patients. In Luminal B1 patients 
high PgR expression was found in older patients, while in Luminal B2 patients ER and PgR expression 




Ki-67 <=20% Ki-67 >20%
Age <55 years Age >54 years Total Age <55 years Age >54 years Total
Breast cancer type Luminal A Luminal B1
ER 0-2+ 16 10 26 12 8 20
ER3+ 104 310 414 76 167 243
Total 120 320 440 88 175 263
Χ2(p) 16.36 (0.0001) 6.85 (0.0089)
PgR 0-2+ 18 78 96 24 64 88
PgR3+ 102 242 344 64 111 175
Total 120 320 440 88 175 263
Χ2(p) 4.50 (0.034) 2.27 (0.1316)
Breast cancer type Luminal B2
ER 0-2+ 5 3 8 5 6 11
ER3+ 21 52 73 34 72 106
Total 26 55 81 39 78 117
Χ2(p) 3.76 (0.0524) 0.80 (0.3703)
PgR 0-2+ 10 23 33 15 41 56
PgR3+ 16 32 48 24 37 61
Total 26 55 81 39 78 117
Χ2(p) 0.08 (0.7741) 2.07 (0.1500)
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cancer patients and matched controls (22). The results 
showed that the association of endogenous estrogens with 
breast cancer risk is independent of the tumor ER status. 
These results were also interpreted as more compatible 
with the hypothesis of a progression from ER positive to 
ER negative tumors than with the hypothesis that ER 
status identifies two distinct types of breast cancer. Re-
sults that link tamoxifen and raloxifen as selective estro-
gen receptor modulators (SERM) with the reduced oc-
currence of only ER positive tumors strongly support the 
etiological distinction between ER positive and ER nega-
tive breast cancers. Tamoxifen prevention trials showed 
no effect for ER negative breast cancers, but ER positive 
cancers were decreased by 48% (25). In 8981 breast can-
cer patients older than 50, tamoxifen decreases only the 
risk of ER positive contralateral breast tumors (26). Ral-
oxifene was shown to reduce the risk of both in situ and 
invasive breast cancer by 65%, with the most significant 
risk reduction in women who developed ER positive can-
cers (27).
It was reported that despite the menopausal status, the 
expression of ER and PR in normal breast tissue is highly 
variable, with many apparently negative cells (28). In pre-
menopausal normal breast tissue, 6% of cells are ER 
positive and 29% PR positive (29). Beside that, expression 
of ER declines in the normal breast tissue as the men-
TablE 3
An attempt to estimate how much of the here presented patients might have acquired steroid 
receptors during cancerogenesis (shown in shaded table fields), beside the already recognized 
dysfunctional ERs in the ER+PgR– phenotype. The expected numbers are smaller but proportional
to the observed numbers of tumors with low PgR expression (shown in the bottom table section).
Steroid receptor positive breast cancer types Symbols & formulas Luminal A Luminal B1
Proposed Ki-67/Luminal B2 
subgroups
<=20% >20%




+PgR+ Ph1 405 229 69 96
cancerogenesis 
associated
ER+PgR- Ph2 29 29 12 21
ER-PgR+ Ph3 6 5 0 0
Total C 440 263 81 117
Probability of tissue or cancerogenesis associated PgR expres-
sion (D) Ph1/C 0.9205 0.8707 0.8519 0.8205
Predicted breast cancers with tissue associated ER+PgR+ phenotypes
Predicted breast cancers with 
tissue associated ER+PgR+ 
phenotypes
Predicted share (%) D2 84.72% 75.82% 72.57% 67.32%
Predicted number of patients 
with functional ER D
2*C 372.8 199.4 58.8 78.8
Observed frequencies of ER+PgR+ phenotypes with full PgR expression 
Number of patients with:
ER3+ and PgR3+ phenotype 325 168 45 58
ER2+ and PgR3+ phenotype 8 4 3 1
ER1+ and PgR3+ phenotype 5 3 0 2
Total 338 175 48 61
Predicted breast cancers with cancerogenesis associated ER+PgR+ phenotypes
Predicted breast cancers with 
cancerogenesis associated 
ER+PgR+ phenotypes
Predicted share (%) E=D-D2 7.32% 11.26% 12.62% 14.73%
Predicted number of patients 
with potentially dysfunctional 
ER (dysf.pred)
E*C 32.2 29.6 10.2 17.2
Observed frequencies of ER+PgR+ phenotypes with reduced PgR expression 
Number of patients with:
ER3+ and PgR1+ phenotype 40 26 11 24
ER3+ and PgR2+ phenotype 23 24 6 6
ER2+ and PgR1+ phenotype 2 2 1 2
ER2+ and PgR2+ phenotype 0 0 2 1
ER1+ and PgR1+ phenotype 2 0 1 1
ER1+ and PgR2+ phenotype 0 2 0 1
Total number of tumors with low PgR expression 67 54 21 35
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strual cycle progresses (30) and tamoxifen therapy in-
creases the mean percentage ER positivity in normal 
ductal tissue (28). During breast development, ER and 
PR are almost absent in fetal and infant breasts, while 
their expression is high in the epithelial cells of the puber-
tal breast (31). Levels of mRNA expression of the ER gene 
depend on the hormonal status, with relatively higher 
levels in breasts of perimenarchal girls, and women in the 
luteal phase of the menstrual cycle, and in those with fi-
brocystic changes (32).
4.1. the role of dysfunctional Er
This surplus of ER+PgR+ tumors among tumors with 
low HER2 expression and low mitotic activity suggests 
two things:
a)  some of these tumors might have originated from 
ER negative progenitor cells and later aquired their 
ER;
b)  phenotypic change due to ER expression might have 
been particularly important in cancerogenesis of 
these tumors.
From several studies (6–12), it is well established that 
PgR expression in cells with ER depends on estrogen ex-
posure during previous days, suggesting that ligand bind-
ing to ER is a physiologic prerequisite of PgR expression 
and the accepted concept is that ER+PgR- breast tumor 
phenotype is caused by dysfunctional ER action upon 
ligand binding.
When considering progesterone binding to PgR, sev-
eral reports show that progesterone exposure diminishes 
both ER and PgR expression in target tissues. Lundgren 
et al. (8) have reported that high dose oral gestagen di-
minishes PgRs and reduces ERs and androgen receptors 
in the breast cancer tissue. Vereide et al. (12) have found 
in uterine mucosa that gestagen reduces glandular and 
stromal PgRs and ERs. Likewise, it is mentioned in the 
textbook by Boron and Boulpaep (20) that “Progestins 
are also antiestrogens. As a result, progestins acting lo-
cally may downregulate estrogen receptors and reduce the 
effectiveness of estradiol.”
These two interactions between ligand binding and 
steroid receptor expressions in estrogen dependent tissues, 
can make a solid regulatory frame during the ovulatory 
cycle (5). Preovulatory estrogen exposure initiates tissue 
activity and increases PgR presence. During the luteal 
phase, progesterone binding to PgR slowly diminishes 
both ER and PgR expression in target tissues and dimin-
ishes all estrogen-induced actions, if no pregnancy has 
occurred.
Here tested model proposes that ligand binding to 
dysfunctional ERs can also lead to weak PgR expression, 
allowing that some of ER+PgR+ tumors might also have 
dysfunctional ERs. As an explanation of dyscrepancy be-
tween to probably very few ER+ progenitor cells in breast 
ducts and many ER+ ductal cancers, a proposition is made 
that most of the tumors with dysfunctional ERs come 
from ER- progenitor cells that acquired ER expression 
during cancerogenesis. In this case, weak or absent PgR 
expression upon the ER ligand binding is considered 
much more probable than in breast tumors developed 
from ER+ progenitor cells.
4.2. Possible differences in tumor 
biology of tumors with dysfunctional 
Ers
In Luminal B1 tumors, an increased share of 
ER3+PgR3+ phenotype was found in all patients and par-
ticularly in patients older than 54 years. Only in Luminal 
B2 with Ki-67 values >20%, an increased share of 
ER3+PgR3+ tumors was found in older patients (). A pos-
sible explanation is that functional ER are upregulated in 
the menopausal setting, estrogen binding helps express 
PgR, while the lack of progesterone exposure allows high 
ER and PgR levels. Among 397 Luminal A patients, re-
duced ER expression was more common in younger pa-
tients (p<0.0001), possibly reflecting premenopausal hor-
mone exposures. A similar situation was with Luminal B1 
patients (p=0.0382). In Luminal B1 patients high PgR 
expression was found in older patients (p=0.0337), pos-
sibly due to lack of progesterone exposure.
The model predicts that at least 39 of these 301 
ER+PgR+ patients might have potentialy dysfunctional 
ERs. If estrogen binding to ER in these tumors only par-
tially express PgR, the reduced PgR availability dimin-
ishes progesterone suppression of ER and PgR expression, 
making tumor cells more susceptible to estrogen stimula-
tion.
The greatest share of model predicted dysfunctional 
ER+PgR+ tumor phenotypes was expected in Luminal B2, 
particularly in these tumors with Ki-67 >20% and pre-
dicted numbers correlate with the number of patients 
with ER3+PgR1+ tumors.
It seems that estrogen binding to ER in some Luminal 
A, B1, or B2 tumors only partially expresses PgR, result-
ing in a dysfunctional variant of the ER+PgR+ phenotype. 
If this reduces progesterone suppression of ER and PgR 
expressions, these tumor cells can become more suscep-
tible to estrogen stimulation.
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